<DOC>
	<DOCNO>NCT00683722</DOCNO>
	<brief_summary>The objective present study establish safety efficacy multiple administration PROCHYMAL™ ( human adult stem cell ) subject moderate severe Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>PROCHYMAL™ ( Human Adult Stem Cells ) Treatment Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>COPD currently fourth lead cause death United States . It clear significant unmet medical need safe effective therapy treat moderate severe COPD . This patient population high mortality rate require frequent hospitalization due disease-related exacerbation . Based severity distribution estimate , approximately 70 % current COPD patient either moderate severe COPD . COPD known cure , thus current therapeutic intervention aim provide relief symptom . Oxygen therapy treatment show improve survival . Smoking cessation show slow rate FEV1 decline COPD progression . In general patient treat bronchodilator inhaled corticosteroid , , measure provide significant benefit regard disease progression prognosis . The characteristic biologic activity PROCHYMAL™ , along good safety profile human trial date , suggest PROCHYMAL™ may good candidate address unmet medical need .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<criteria>Subject must diagnosis moderate severe COPD Subject must postbronchodilator FEV1/FVC ratio &lt; 0.7 Subject must postbronchodilator FEV1 % predict value ≥ 30 % &lt; 70 % Subject must 40 80 year age , either sex , race Subject must current exsmoker , cigarette smoke history ≥ 10 year &gt; 10 packyears Subject diagnose asthma clinically relevant lung disease COPD ( e.g . restrictive lung disease , sarcoidosis , tuberculosis , idiopathic pulmonary fibrosis , bronchiectasis , lung cancer ) Subject diagnose α1Antitrypsin deficiency Subject body mass great 150 kg ( 330 lb ) less 40 kg ( 88 lb ) Subject active infection Subject significant exacerbation COPD require mechanical ventilation within 4 week screen Subject clinically relevant uncontrolled medical condition associate COPD Subject document history uncontrolled heart failure Subject pulmonary hypertension due leave heart condition Subject atrial fibrillation significant congenital heart defect/disease Subject initiate pulmonary rehabilitation within 3 month screen Subject allergic bovine porcine product Subject evidence active malignancy , prior history active malignancy remission least 5 year Subject life expectancy &lt; 6 month</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>COPD</keyword>
	<keyword>Airflow Obstruction , Chronic</keyword>
	<keyword>Chronic Airflow Obstruction</keyword>
	<keyword>Chronic Obstructive Airway Disease</keyword>
	<keyword>Chronic Obstructive Lung Disease</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Pulmonary Emphysema</keyword>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>MSCs</keyword>
	<keyword>Adult Human Stem Cells</keyword>
	<keyword>Osiris</keyword>
	<keyword>Prochymal</keyword>
</DOC>